Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Pediatric Clinical Trials

Brain/CNS

Protocol COG ACNS1422
Cancer Type: Medulloblastoma
Fast Facts

A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be Greater than or Equal to 3 Years and Less than 22 Years of Age at the Time of Enrollment on ACNS1422 Step 0.

Protocol COG ACNS1721
Cancer Type: High-Grade Glioma
Fast Facts

A Phase II Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation,Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

Patients >21 Years must be IDH Mutant.

Note: At the time of ACNS1721 Step 1 enrollment, patients will be stratified and age is a factor.

Protocol COG ACNS1723
Cancer Type: High-Grade Glioma
Fast Facts

A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

Protocol COG ACNS1831
Cancer Type: Low-Grade Glioma
Fast Facts

A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in 
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.

Protocol COG ACNS1833
Cancer Type: Low-Grade Glioma
Fast Facts

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.

Protocol COG-ACNS1931
Cancer Type: Low Grade Glioma
Fast Facts

COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.

Protocol COG ANBL00B1
Cancer Type: Neuroblastoma-Biology
Fast Facts

Neuroblastoma Biology Studies

All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study. 

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Care Delivery (CCDR)

Protocol COG ACCL16N1CD
Cancer Type: Acute Lymphoblastic Leukemia (ALL)

Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Control

Protocol COG ALTE03N1
Cancer Type: Multi-site Cancer Control
Fast Facts

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Protocol COG ALTE07C1
Cancer Type: Multi-Site Cancer Control
Fast Facts

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Protocol COG ACCL16N1CD
Cancer Type: Acute Lymphoblastic Leukemia (ALL)

Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

Please check out the rare protocol list to locate other studies within this disease site.

Gastrointestinal

Protocol COG AHEP1531
Cancer Type: PHITT
Fast Facts

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Age: Patients must be ≤ 30 Years of Age at the Time of Diagnosis

Please check out the rare protocol list to locate other studies within this disease site.

Genitourinary

Protocol COG AREN1921
Cancer Type: Wilms
Fast Facts

COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Patients must be ≤ 30 years old at study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AREN03B2
Cancer Type: Renal-Biology
Fast Facts

Renal Tumors Classification, Biology, and Banking Study 

Patients must be < 30 Years Old at the Time of Diagnosis.

Please check out the rare protocol list to locate other studies within this disease site.

Germ Cell

Protocol COG AGCT1531
Cancer Type: Germ Cell
Fast Facts

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

  1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
    Patients must be < 50 Years of Age at Enrollment.
  2. Standard Risk 1
    Patient must be < 11 Years of Age at Enrollment.
  3. Standard Risk 2
    Patients must be ≥ 11 and < 25 Years of Age at Enrollment.

Protocol COG AGCT1532
Cancer Type: Germ Cell
Fast Facts

Phase III Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Age ≥ 11 Years and ≤ 45 Years on the Date of Randomization

Please check out the rare protocol list to locate other studies within this disease site.

Leukemia

Protocol COG AAML1831
Cancer Type: de nova AML
Fast Facts

COG-AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Patients must be less than 22 years of age at the time of study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AALL15P1
Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Fast Facts

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Infants Less than 1 Year of Age on the Date of Diagnosis are Eligible; Infants must be >36 Weeks Gestational Age at the Time of Enrollment.

Protocol COG AALL1621
Cancer Type: Relapsed Refractory CD22 B-ALL
Fast Facts

A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.

Protocol COG AALL1521
Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Fast Facts

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Age ≥ 1 Year and ≤ 21 Years at Time of Leukemia Diagnosis.

Protocol COG AALL1631
Cancer Type: Ph+ ALL
Fast Facts

International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Age:  > 1 Year and < 21 Years at ALL Diagnosis

Protocol COG ACCL16N1CD
Cancer Type: Acute Lymphoblastic Leukemia (ALL)

Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

Protocol COG AALL1731
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS)

Partial/Temporary Closure to Accrual - Down syndrome strata (Stratum 2 and Stratum 3)

Protocol COG AALL1732
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Patients must be > 365 Days and < 25 Years of Age

Protocol COG AAML1531
Cancer Type: AML
Fast Facts

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Children with Down Syndrome > 90 Days and < 4 Years of Age at Diagnosis of AML or Myelodysplastic Syndrome (MDS) 

Protocol COG AALL1821
Cancer Type: B-ALL
Fast Facts

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Enrollment to Group 2/3 Stratum on AALL1821 has been temporarily closed to accrual as of March 22nd, 2021.

Please check out the rare protocol list to locate other studies within this disease site.

Lymphoma

Protocol COG ANHL1931
Cancer Type: Lymphoma
Fast Facts

COG ANHL1931

A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

This is an AYA protocol  ≥ 2 years

Please check out the rare protocol list to locate other studies within this disease site.

Multisite

Protocol COG ALTE2031
Cancer Type: multisite
Fast Facts

ALTE2031 - StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors

Patient must be ≥15 years and < 21 years at the time of enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AGCT1531
Cancer Type: Germ Cell
Fast Facts

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

  1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
    Patients must be < 50 Years of Age at Enrollment.
  2. Standard Risk 1
    Patient must be < 11 Years of Age at Enrollment.
  3. Standard Risk 2
    Patients must be ≥ 11 and < 25 Years of Age at Enrollment.

Protocol COG APEC14B1
Cancer Type: All patients
Fast Facts

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Protocol COG ALTE03N1
Cancer Type: Multi-site Cancer Control
Fast Facts

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Protocol COG ALTE05N1
Cancer Type: Multisite Long Term Follow-up
Fast Facts

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

Protocol COG ALTE07C1
Cancer Type: Multi-Site Cancer Control
Fast Facts

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Protocol COG APEC1621 – MATCH Protocol SC
Cancer Type: Screening
Fast Facts

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Protocol COG APEC1621 - MATCH
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

Protocol COG APEC1621 - MATCH Protocol A
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol B
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol D
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors


Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol F
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 – MATCH Protocol G
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

Protocol COG APEC1621 – MATCH Protocol H
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 – MATCH Protocol I
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol K
Cancer Type: Molecular

APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol M
Cancer Type: Molecular

APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations

Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621N
Cancer Type: Molecular

APEC1621N: NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG ARST1921
Cancer Type: Other
Fast Facts

COG-ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Neuroblastoma

Protocol COG ANBL00B1
Cancer Type: Neuroblastoma-Biology
Fast Facts

Neuroblastoma Biology Studies

All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study. 

Protocol COG ANBL1232
Cancer Type: NBL
Fast Facts

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

TEMPORARY CLOSURE for Group C (Groups A1 and B Remain Open)

Protocol COG ANBL1531
Cancer Type: High-Risk Neuroblastoma
Fast Facts

A Phase III Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Age - Patient must be ≥ 365 Days and ≤ 30 Years of Age at Diagnosis.

ARM C perm closed

Protocol COG ANBL1821
Cancer Type: Neuroblastoma
Fast Facts

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

 

Patients ≥ 1 year of age at the time of enrollment are eligible for this study.

Please check out the rare protocol list to locate other studies within this disease site.

Sarcoma

Protocol COG ARST1431
Cancer Type: IR Rhabdomyosarcoma
Fast Facts

A Randomized Phase III Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Feasibility Phase: Patients must be < 21 Years of Age at the Time of Enrollment.
Efficacy Phase: Patients must be ≤ 40 Years of Age at the Time of Enrollment.

Protocol COG ALTE16C1
Cancer Type: Sarcoma
Fast Facts

Effects of Modern Chemotherapy Regimens on  spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

Patients must be ≥ 18 and ≤ 50 Years of Age at the Time of Enrollment

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.